ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Currax Pharmaceuticals: CONTRAVE?/MYSIMBA? Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study Biotech Newswire
August 28, 2024Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk. -
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE?/MYSIMBA? Amidst GLP-1 Supply Issues Biotech Newswire
July 24, 2024Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE?/MYSIMBA? in the European Union and European Union Economic Areas.
Pharma Sources Insight January 2025
